{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:01:24Z","timestamp":1790128884664,"version":"4.0.1"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ctrv.2020.102083","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T21:37:40Z","timestamp":1595021860000},"page":"102083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Melanoma brain metastases \u2013 Interdisciplinary management recommendations 2020"],"prefix":"10.1016","volume":"89","author":[{"given":"Ralf","family":"Gutzmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Vordermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Krex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sickmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Pukrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"H\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-2770","authenticated-orcid":false,"given":"Thomas K.","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102083_b0005","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.102083_b0010","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/1097-0142(19840601)53:11<2550::AID-CNCR2820531129>3.0.CO;2-B","article-title":"Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience","volume":"53","author":"Madajewicz","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0015","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","article-title":"Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials","volume":"37","author":"Gaspar","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2020.102083_b0020","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0025","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0030","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ijrobp.2017.06.2454","article-title":"Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (Melanoma-molGPA)","volume":"99","author":"Sperduto","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102083_b0035","article-title":"Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients","volume":"8","author":"Amaral","year":"2020","journal-title":"J Immounther Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0040","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0045","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2020.102083_b0050","doi-asserted-by":"crossref","first-page":"9501","DOI":"10.1200\/JCO.2019.37.15_suppl.9501","article-title":"Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204)","volume":"37","author":"Tawbi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0055","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0065","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0070","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1470-2045(12)70324-8","article-title":"Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial","volume":"13","author":"Di Giacomo","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0075","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0080","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0085","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0090","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdw641","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study","volume":"28","author":"McArthur","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0095","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study","volume":"50","author":"Dummer","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0100","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdl148","article-title":"Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG\/ADO study","volume":"17","author":"Schadendorf","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0105","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2004.11.044","article-title":"Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study","volume":"22","author":"Agarwala","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0110","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study","volume":"22","author":"Avril","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0115","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/1097-0142(19901101)66:9<1873::AID-CNCR2820660904>3.0.CO;2-5","article-title":"Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases","volume":"66","author":"Jacquillat","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0120","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.2147\/CMAR.S204729","article-title":"Whole-brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma - final results of the BRAIN-RT trial","volume":"11","author":"Hauswald","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2020.102083_b0125","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1200\/JCO.2018.36.15_suppl.9546","article-title":"Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22)","volume":"36","author":"Lopez-Martin","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00008390-200302000-00016","article-title":"A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma","volume":"13","author":"Mornex","year":"2003","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102083_b0135","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1200\/JCO.19.01414","article-title":"Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase III trial","volume":"37","author":"Hong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1215\/15228517-2007-058","article-title":"Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features","volume":"10","author":"Raizer","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0145","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/cncr.25631","article-title":"Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma","volume":"117","author":"Eigentler","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0150","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3171\/2013.9.JNS13596","article-title":"Postoperative ischemic changes following brain metastasis resection as measured by diffusion-weighted magnetic resonance imaging","volume":"119","author":"Gempt","year":"2013","journal-title":"J Neurosurg"},{"issue":"Suppl 6","key":"10.1016\/j.ctrv.2020.102083_b0155","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.4103\/2152-7806.121632","article-title":"Stereotactic radiosurgery boost to the resection cavity for cerebral metastases: Report of overall survival, complications, and corticosteroid protocol","volume":"4","author":"Kellogg","year":"2013","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.ctrv.2020.102083_b0160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2407-14-21","article-title":"Risks of postoperative paresis in motor eloquently and non-eloquently located brain metastases","volume":"14","author":"Obermueller","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0165","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952\u201326001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0170","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0175","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.radonc.2019.08.024","article-title":"Post-operative stereotactic radiosurgery following excision of brain metastases: A systematic review and meta-analysis","volume":"142","author":"Akanda","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0185","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0190","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1748-717X-7-77","article-title":"Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment","volume":"7","author":"Tallet","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0195","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2020.102083_b0200","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A randomized trial of surgery in the treatment of single metastases to the brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102083_b0205","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ana.410330605","article-title":"Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?","volume":"33","author":"Vecht","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ctrv.2020.102083_b0210","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>3.0.CO;2-X","article-title":"A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis","volume":"78","author":"Mintz","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0215","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.280.17.1485","article-title":"Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial","volume":"280","author":"Patchell","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2020.102083_b0220","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0360-3016(01)02772-9","article-title":"Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery","volume":"52","author":"Yu","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2020.102083_b0225","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.1200\/JCO.2005.01.8747","article-title":"Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397)","volume":"23","author":"Manon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0230","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2020.102083_b0235","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijrobp.2017.04.006","article-title":"Single-fraction stereotactic radiosurgery (SRS) alone versus surgical resection and SRS for large brain metastases: a multi-institutional analysis","volume":"99","author":"Prabhu","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2020.102083_b0240","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11060-017-2394-z","article-title":"Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases","volume":"132","author":"Minniti","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0245","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000489948","article-title":"Gamma knife radiosurgery for metastatic brain tumors from malignant melanomas: a japanese multi-institutional cooperative and retrospective cohort study (JLGK1501)","volume":"96","author":"Matsunaga","year":"2018","journal-title":"Stereotact Funct Neurosurg"},{"key":"10.1016\/j.ctrv.2020.102083_b0250","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant Nivolumab and Ipilimumab or Nivolumab versus Placebo in resected Stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.102083_b0255","doi-asserted-by":"crossref","unstructured":"Han EY, Wang H, Luo D, Li J, Wang X. Dosimetric comparison of fractionated radiosurgery plans using frameless Gamma Knife ICON and CyberKnife systems with linear accelerator-based radiosurgery plans for multiple large brain metastases. J Neurosurg 2019;5:1-7. doi: 10.3171\/2019.1.JNS182769.","DOI":"10.3171\/2019.1.JNS182769"},{"key":"10.1016\/j.ctrv.2020.102083_b0260","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/imt-2018-0149","article-title":"Immunotherapy plus surgery\/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis","volume":"11","author":"Amaral","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctrv.2020.102083_b0265","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2018-0306","article-title":"Upfront surgical resection of melanoma brain metastases provides a bridge toward immunotherapy-mediated systemic control","volume":"24","author":"Alvarez-Breckenridge","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2020.102083_b0270","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0275","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.2, 2019, AWMF Registernummer: 032\/024OL, http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/melanom\/ [accessed Feb 26, 2020]."},{"key":"10.1016\/j.ctrv.2020.102083_b0280","doi-asserted-by":"crossref","unstructured":"Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, et al. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019;17:367\u2013402. doi: 10.6004\/jnccn.2019.0018.","DOI":"10.6004\/jnccn.2019.0100"},{"key":"10.1016\/j.ctrv.2020.102083_b0285","unstructured":"Hong A, Taing C, Long G, Carlino M, Shivalingam B, Cancer council australia melanoma guidelines working party. When is radiation therapy indicated for patients with distant brain metastases? https:\/\/wiki.cancer.org.au\/australiawiki\/index.php?oldid=199467 [accessed Feb 26, 2020]."},{"key":"10.1016\/j.ctrv.2020.102083_b0290","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0295","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III Trial NRG Oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.ctrv.2020.102083_b0300","first-page":"S265","article-title":"Carcinomatous meningitis: Leptomeningeal metastases in solid tumors","volume":"4","author":"Le Rhun","year":"2013","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.ctrv.2020.102083_b0305","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11060-019-03121-2","article-title":"Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD)","volume":"142","author":"Ferguson","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0310","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/pcmr.12771","article-title":"Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities","volume":"32","author":"Eroglu","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102083_b0315","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-13-3003","article-title":"Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target","volume":"20","author":"Chen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102083_b0320","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cam4.50","article-title":"Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases","volume":"2","author":"Niessner","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2020.102083_b0325","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10585-017-9864-8","article-title":"Metabolic advantages and vulnerabilities in brain metastases","volume":"34","author":"Ciminera","year":"2017","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ctrv.2020.102083_b0330","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1158\/0008-5472.CAN-14-1392","article-title":"Inhibition of mTORC1\/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1\u03b1 and oxidative phosphorylation in melanoma","volume":"74","author":"Gopal","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102083_b0335","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1158\/1541-7786.MCR-09-0234","article-title":"Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis","volume":"7","author":"Palmieri","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102083_b0340","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/pcmr.12861","article-title":"Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions","volume":"33","author":"Glitza","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102083_b0345","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/CMR.0000000000000162","article-title":"Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma","volume":"25","author":"Sakji-Dupr\u00e9","year":"2015","journal-title":"Melanoma Res"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2020.102083_b0350","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.1200\/JCO.2020.38.15_suppl.10008","article-title":"Single-center phase I\/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD)","volume":"38","author":"Glitza","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0355","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000283","article-title":"Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2","volume":"3","author":"Glitza","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2020.102083_b0360","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0365","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"Fuc\u00e0","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2020.102083_b0370","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system","volume":"79","author":"Levin","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2020.102083_b0375","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0380","doi-asserted-by":"crossref","first-page":"pii: E546","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2020.102083_b0385","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdw417","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0390","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2018.12.023","article-title":"Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases","volume":"110","author":"Rauschenberg","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0395","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2019.02.009","article-title":"Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort","volume":"112","author":"T\u00e9tu","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0400","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102083_b0405","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.12.024","article-title":"Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma","volume":"109","author":"Shannan","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0410","article-title":"Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma","volume":"8","author":"Pfannenstiel","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2020.102083_b0415","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","article-title":"Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases","volume":"9","author":"Fischer","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2020.102083_b0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2016.08.003","article-title":"Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?","volume":"50","author":"Franceschini","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2020.102083_b0425","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1046028","article-title":"A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab","volume":"4","author":"Chandra","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2020.102083_b0430","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0435","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000395","article-title":"Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG","volume":"8","author":"Knispel","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0440","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ijrobp.2016.01.038","article-title":"Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the eastern cooperative oncology group (ECOG)","volume":"95","author":"Anker","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2020.102083_b0445","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/pcmr.12775","article-title":"Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies","volume":"32","author":"Pires da Silva","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102083_b0450","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14737175.2016.1184572","article-title":"Radionecrosis after stereotactic radiotherapy for brain metastases","volume":"16","author":"Le Rhun","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.ctrv.2020.102083_b0455","first-page":"v533","article-title":"Safety and efficacy of triplett combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients with BRAF-mutated metastatic melanoma: a single center phase II study","volume":"30_suppl 5","author":"Burton","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0460","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2020.102083_b0465","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1200\/JCO.2020.38.15_suppl.10023","article-title":"Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study","volume":"38","author":"Ascierto","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0470","article-title":"Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, Progression, and Pseudoprogression","volume":"Aug 22","author":"Galldiks","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0475","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0480","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102083_b0485","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2006.01.026","article-title":"RECIST revisited: a review of validation studies on tumour assessment","volume":"42","author":"Therasse","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0490","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response Assessment in Neuro-Oncology (RANO) group. Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0495","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0500","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0505","doi-asserted-by":"crossref","unstructured":"Bohnsack O, Hoos A, Ludajic K. Adaptation and modification of the immune related response criteria (IRRC): IrRECIST. J Clin Oncol 2014;32:15_suppl, e22121. doi: 10.1200\/jco,2014.32.15_suppl.e22121.","DOI":"10.1200\/jco.2014.32.15_suppl.e22121"},{"key":"10.1016\/j.ctrv.2020.102083_b0510","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","article-title":"Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy","volume":"36","author":"Hodi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0515","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0520","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0525","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102083_b0530","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102083_b0535","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12935-019-0938-3","article-title":"Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAFv600e mutated melanoma cells in vitro","volume":"19","author":"Scatena","year":"2019","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ctrv.2020.102083_b0540","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.102083_b0545","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102083_b0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0555","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/CMR.0000000000000268","article-title":"BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102083_b0560","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3171\/2015.6.JNS142763","article-title":"Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?","volume":"125","author":"Colaco","year":"2016","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2020.102083_b0565","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/CMR.0000000000000413","article-title":"Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases","volume":"28","author":"Nardin","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102083_b0570","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3389\/fonc.2018.00395","article-title":"Diagnosis and management of radiation necrosis in patients with brain metastases","volume":"8","author":"Vellayappan","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0575","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/neuonc\/now154","article-title":"Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases","volume":"18","author":"Kebir","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0580","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/2326-6066.CIR-15-0238","article-title":"Possible interaction of anti-PD-1 therapy with the effects of radiosurgery on brain metastases","volume":"4","author":"Alomari","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2020.102083_b0585","doi-asserted-by":"crossref","first-page":"11832","DOI":"10.3390\/ijms150711832","article-title":"The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence","volume":"15","author":"Parvez","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2020.102083_b0590","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102083_b0595","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2020.102083_b0600","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): Evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2020.102083_b0605","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management","volume":"4","author":"Heinzerling","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2020.102083_b0610","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.clineuro.2013.03.019","article-title":"Intracerebral metastases of malignant melanoma and their recurrences\u2013a clinical analysis","volume":"115","author":"Miller","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.ctrv.2020.102083_b0615","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3171\/jns.2000.93.1.0009","article-title":"Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients","volume":"93","author":"Wro\u0144ski","year":"2000","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2020.102083_b0620","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2017.07.017","article-title":"Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery","volume":"84","author":"Gaudy-Marqueste","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2019.08.011","article-title":"Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery","author":"McTyre","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2020.102083_b0630","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.wneu.2019.10.101","article-title":"Purely meningeal intracranial relapse of melanoma brain metastases after surgical resection and immunotherapy as a unique disease progression pattern: our experience and review of the literature","volume":"134","author":"Armocida","year":"2019","journal-title":"World Neurosurgery"},{"key":"10.1016\/j.ctrv.2020.102083_b0635","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1186\/s12885-018-4470-y","article-title":"Unmasking of intracranial metastatic melanoma during ipilimumab\/nivolumab therapy: case report and literature review","volume":"18","author":"McDonald","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0640","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/cncr.32547","article-title":"Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series","volume":"126","author":"Holbrook","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102083_b0645","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2020.102083_b0650","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","article-title":"Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases","volume":"9","author":"Fischer","year":"2019","journal-title":"Cancer Discov"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:24:00Z","timestamp":1759656240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220301213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":130,"alternative-id":["S0305737220301213"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102083","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melanoma brain metastases \u2013 Interdisciplinary management recommendations 2020","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102083"}}